药物化学中构效关系的教学方法研究

构效关系是先导化合物修饰、新型药物设计的基础,在药物化学教学中具有至关重要的作用.由于其多样性和复杂性,学生的掌握情况不理想.本文针对这一问题对药物的构效关系进行归纳分类,总结为"三部分一核心多构型"三类,每一类都进行举例讲解,为学生更好地理解与掌握药物化学的构效关系提供一种可行的方式.     

抗高血压药物的构效关系研究进展

我国对抗高血压药的研究始于20世纪50年代。随着研究的不断深入,抗高血压药物朝着高效、长效、高度心血管选择性、多器官保护作用以及低副作用方向发展,不断在原有化合物模型的基础上对化合物进行结构修饰,发展了单环及多环含氮杂环类抗高血压药物。文章从结构与活性的角度分析了近年来国内外杂环类抗高血压药及其衍生物的构效关系。     

喜树碱类抗肿瘤药物作用模式的柔性分子对接研究

研究采用柔性分子对接技术，将15个喜树碱类化合物对接到拓扑异构酶I (Topo I)-DNA切割复合物中，从原子水平和分子力场角度阐明了喜树碱类抗肿瘤药 物与DNA，Topo I的相互作用机制。研究发现，喜树碱分子插入Topp I-DNA复合物 的切割位点，并与Asn722，Asp533，Lys532和Lys720形成氢键作用网络。定量构效 关系研究进一步表明喜树碱分子可以与Topo I-DNA切割复合物形成电荷迁移作用。 该对接模型系统解释了喜树碱类化合物的构效关系、定点突变等诸多实验事实，为 下一步设计、合成新型高效的喜树碱类衍生物打下了坚实基础。     

喜树碱结构与活性的关系

喜树碱是从我国特有植物喜树中分离得到的。它是一种广谱抗癌药物，对多种肿瘤有疗效，但同时也有副作用。为了寻找一种既具抗癌活性，毒性又小的喜树碱类似物，国外学者对喜树的五个环分别进行了修饰，并对修饰产物进行了药理研究，找到了抗癌活性与结构之间的关系。本文着重介绍他们的研究结果并简要总结一下喜树碱的结构、性质。     

黄酮类化合物结构修饰及抗肿瘤活性研究进展

我国天然药物和中药资源丰富,种类繁多,可作为先导化合物进行修饰以提高可成药性。其中,黄酮类化合物是自然界中一种常见的天然多酚类化合物,在抗肿瘤方面具有其独特的生物活性;对其进行结构修饰与改造,可提高黄酮类化合物的生物利用度和抗肿瘤活性。本文通过查阅并整理近几年国内外的黄酮类化合物的相关文献,对黄酮类化合物的母核位点进行结构修饰与改造所得的101个黄酮类衍生物及其抗肿瘤活性及作用机制进行综述,同时讨论了构效关系,以期为黄酮类衍生物的结构修饰和抗肿瘤研究提供参考和帮助。     

多糖共混及其分子设计

着重讨论了多糖共混过程中的凝胶化及其分子间的协同作用，并对多糖共混凝胶化中的构效关系，分子修饰及分子设计等问题进行了讨论。     

5,7,8位取代的喹诺酮类化合物定量构效关系的量子化学研究

５，７，８位取代的喹诺酮类化合物定量构效关系的量子化学研究俞庆森，朱龙观，林瑞森，蔡国强（浙江大学化学系杭州３１００２７）关键词：氟喹喏酮类，定量构效关系，ＣＮＤＯ／２氟喹诺酮类是一类重要的抗感染化疗药物￣［１］，近十年对其研究进展神速￣［２］，结构...     

用高效液相色谱研究头孢菌素类药物热学函数及其构效关系

本文实验表明反相高效液相色谱流动相组成与头孢菌素容量因子成线性关系，并测定了头孢菌素的过量热力函数△Ｈ，证明头孢菌素类药物的生物活性与ΔＨ存在定量构效关系，从而提出ΔＨ和ΔＳ分别是研究药物定量构效关系的药物生化过程的重要参数之一。     

活性维生素D3类似物的合成及构效关系研究

1α,25-二羟基维生素D₃(1α,25-(OH)₂-D₃,125D)是维生素D中最具生理活性的代谢产物,但因高钙血症副反应而限制其临床应用。从对构效关系的研究出发,迄今已合成三千多种类似物。本文综述了近年来对某些A环修饰(C2位修饰、C3位修饰、芳香A环类似物、A环开环类似物)、侧链修饰、CD环修饰、seco-B环修饰和非开环甾体的活性维生素 D₃ 类似物的设计、合成以及构效关系的研究,旨在为新型较佳活性维生素D₃类似物的合成及临床开发提供参考。     

紫杉醇构效关系研究新进展

综述了近年来在紫杉醇类似物构效研究中的最新进展,按照紫杉醇的A,B, C,D环修饰的顺序总结了新得到的40余种紫杉醇类似物结构与其生物活性之间的关系。     

A theoretical study on camptothecin–AM1 treatment

Camptothecin (irinotecan), a new cytotoxic agent having antitumor activity and especially used in the treatment of advanced colorectal cancers is considered for AM1–RHF type semiempirical quantum chemical treatment together with some analogs of camptothecin. The structural properties and energetics of these molecules have been compared. The structures arising from monoprotonation of camptothecin at various sites are analyzed from thermodynamic point of view.     

Synthesis, Crystal Structure and Antibacterial Activity of 1-（（2-Chloroquinolin-3-yl）-methyl）-pyridin-2（1H）-one

On the basis of the interesting structures and biological activities exhibited by several heterocyclic systems possessing the pyridone nucleus such as mappcine and camptothecin, we have planed to design the synthesis, crystal studies and antibacterial activity of the new 1-((2- chloroquinolin-3yl)-methyl)-pyridine-2(1H)-one building block. An X-ray analysis has provided valuable insight into the effect of steric factors on the three-dimensional shape of this compound which serves as a useful advanced intermediate in the synthesis of these biologically active molecules. A multistep synthesis of camptothecin (5) has been designed by retrosynthetic analysis as part of an ongoing program on lead anticancer drug.     

光谱法比较喜树碱与溶菌酶、过氧化氢酶的相互作用

采用紫外可见吸收、红外、荧光等多种光谱学方法研究了抗癌药物喜树碱和溶菌酶及过氧化氢酶两种蛋白之间的相互作用,结果表明,喜树碱与之均形成基态复合物并引起蛋白内源荧光猝灭。通过计算确定了喜树碱和蛋白相互作用的结合常数、结合位点数、主要作用力类型以及与蛋白中色氨酸的结合距离。喜树碱对过氧化氢酶具有较高的结合能力,这主要是由于喜树碱不仅与过氧化氢酶中的色氨酸存在相互作用,也与酶中的酪氨酸及血红素产生相互作用。喜树碱的存在可引起蛋白构象发生变化,使α-螺旋二级结构减少。     

20(S)-O-喜树碱肉桂酸酯衍生物的合成及其抗肿瘤活性研究

为了提高喜树碱内酯环的稳定性降低其毒性, 增加其抗肿瘤效能, 以喜树碱为先导化合物, 通过酯化反应直接合成了17个20(S)-喜树碱肉桂酸酯衍生物, 并采用MTT法测定了对于人胃癌细胞SGC-7901的体外抗肿瘤活性, 活性测试结果表明有些化合物的抑制活性明显高于母体化合物喜树碱.     

光谱法研究喜树碱与牛血清白蛋白的相互作用

采用多种光谱技术对喜树碱和牛血清白蛋白的相互作用进行了研究.结果表明喜树碱和牛血清白蛋白可形成基态复合物,引起牛血清白蛋白内源荧光猝灭.通过计算获得了二者在不同温度下的结合常数及结合位点数.根据喜树碱和牛血清白蛋白结合的热力学参数,确定了二者之间主要为疏水作用力.根据F(o)rster非辐射能量转移理论确定了喜树碱和牛血清白蛋白的作用距离.同步荧光光谱显示喜树碱主要与蛋白中色氨酸残基发生相互作用,改变其周围的局部构象.红外光谱提示喜树碱可引起蛋白的构象发生改变,α-螺旋二级结构减少.     

Synthesis and antitumor activity of 9-methyl-10-hydroxycamptothecin

A novel camptothecin analogue, 9-methyl-10-hydroxycamptothecin （4）, was unexpectedly synthesized from 10-hydroxycamptothecin in two steps. The key step included an efficient Mannich-type reaction. The overall yield was 47.2%. An ether analogue of 4, 9-methyl-10-benzylaminomethoxycamptothecin （5）, was also prepared. These new camptothecin analogues were evaluated for in vitro cytotoxicity against four human cancer cell lines, and exhibited more potent antitumor activities than contrals camptothecin and topotecan against several cancer cells.     

Inclusion of chemotherapeutic agents in substituted ��-cyclodextrin derivatives

The stabilities of the inclusion compounds of three chemotherapeutic agents, camptothecin (CPT), docetaxel (DOC) and idarubicin (IDA), plus a model compound 1,4-dihydroxyanthraquinone (DHA) with several ??-cyclodextrin (??-CD) derivatives were investigated by solubility measurements, isothermal titration microcalorimetry and fluorescence anisotropy measurements. Ionic heptakis-(6-deoxy-6-thioethers) of ??-CD were found to exhibit very high binding potentials for these drugs making them to good candidates for advanced drug delivery.     

Measurement and pharmacokinetics of unbound 20(S)-camptothecin in rat blood and brain by microdialysis coupled to microbore liquid chromatography with fluorescence detection

To characterize the pharmacokinetics of protein-free camptothecin in blood and brain we implanted microdialysis probes into the jugular vein and striatum of rats for unbound drug sampling and determination. Camptothecin (2 or 5 mg/kg, i.v., n=6) was then administered from the femoral vein, and microdialysates were collected from blood and brain of both sites and assayed by a validated microbore scale high-performance liquid chromatographic method. The mobile phase consisted of methanol–100 mM monosodium phosphoric acid (35:65, v/v, pH 2.5) with a flow-rate 0.05 ml/min. The fluorescence response for camptothecin was observed at excitation and emission wavelengths of 360 and 440 nm, respectively. Pharmacokinetic parameters were calculated from the corrected data for dialysate concentrations of camptothecin versus time. The results suggest that the pharmacokinetics of unbound camptothecin in blood and brain can be fitted best to a two- and one-compartment model, respectively. Camptothecin rapidly entered the extracellular fluid of brain striatum at 10 min following camptothecin administration.     

Determination of Camptothecin and 10-Hydroxycamptothecin in Camptotheca acuminata by LC-ESI-MS/MS

A rapid and sensitive liquid chromatography-tandem mass spectrometry method with multiple reaction monitoring was developed for the simultaneous determination of camptothecin and 10-hydroxycamptothecin in Camptotheca acuminata. The separation of camptothecin and 10-hydroxycamptothecin was performed on an Agilent Eclipse XDB-C18 column with a mixture of methanol and water (1:1, v/v) containing 0.2% formic acid as a mobile phase. The limits of detection of camptothecin and 10-hydroxycamptothecin were 4.0 ng/mL and 7.0 ng/mL (S/N = 3), respectively. Analysis took 10 minutes, making the method suitable for rapid determination of camptothecin and 10-hydroxycamptothecin in C. acuminata.     

20(S)-O-取代苯甲酸-7-乙基喜树碱酯类化合物的合成及其抗肿瘤活性

在AcOH/98％ H2S04体系中,喜树碱和正丙醛经烷基化反应制得7-乙基喜树碱(2);以1-乙基-3-(3-二甲基氨基丙基)碳二亚胺盐酸盐为脱水剂,4-二甲氨基吡啶为催化剂,2与取代苯甲酸直接酯化合成了一系列新型的20(S)-O-取代苯甲酸-7-乙基喜树碱酯类化合物(4a -4k),其结构经1H NMR,IR和MS表征.采用MTT法初步考察了4a～4k对人肺癌细胞(LLC-E9FP),人肺腺癌细胞(95D),人胃癌细胞(BGC-803),人胃癌细胞( HGC-27)和人肝癌细胞(7721)的抑制活性.结果表明,4b和4e对LLC-E9FP具有明显强于喜树碱的抑制活性;4h～4k对HGC-27,95D,7721也有明显的抑制活性.